Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that new data evaluating XOSPATA™ (gilteritinib) across FMS-like tyrosine kinase 3 mutation-positive (FLT3m+) acute myeloid leukemia (AML), including in relapsed or refractory (R/R), newly diagnosed and post-transplant maintenance settings, will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting taking place from 6-9 December 2025 in Orlando, Fla. Through ongoing re…
Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=347646
